Centessa Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Centessa Pharmaceuticals has a total shareholder equity of $499.1M and total debt of $75.7M, which brings its debt-to-equity ratio to 15.2%. Its total assets and total liabilities are $609.7M and $110.6M respectively.
Key information
15.2%
Debt to equity ratio
US$75.70m
Debt
| Interest coverage ratio | n/a |
| Cash | US$518.45m |
| Equity | US$499.14m |
| Total liabilities | US$110.58m |
| Total assets | US$609.72m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 260's short term assets ($568.4M) exceed its short term liabilities ($26.4M).
Long Term Liabilities: 260's short term assets ($568.4M) exceed its long term liabilities ($84.2M).
Debt to Equity History and Analysis
Debt Level: 260 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 260's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 260 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 260 has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 27.3% each year.